Isoflurane

United States Anesthesia Drugs Research Report 2024-2030 with Company Analysis of Baxter International, Abbvie, Medtronic, Draegerwerk, Koninklijke Philips, and Abbott Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, March 11, 2024
Other Consumer, Manufacturing, Other Science, Pharmaceutical, Medical Devices, Hospitals, Consumer, Science, Practice Management, Dental, Managed Care, Medical Supplies, Biotechnology, Surgery, Health, Health Technology, Chemicals, Plastics, Health Insurance, Etomidate, Prevalence, Barbiturate, Isoflurane, Conditional sentence, Patient, Ache, Desflurane, National Cancer Institute, Anesthesiology, Local anesthesia, Health Canada, Survivor, Nitrous oxide, Lidocaine, Society, Cancer, Safety, Plastic, Benzocaine, Anesthetic vaporizer, Dentistry

The "United States Anesthesia Drugs Market, Size, Forecast 2024-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Anesthesia Drugs Market, Size, Forecast 2024-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The demand for anesthesia medicines is rising because of the growing number of surgeries and the approval of recent anesthesia drugs.
  • The United States Anesthesia Drugs Market is assessed into Inhalation Anesthesia, Intravenous Anesthesia, and Local Anesthesia.
  • The General Anesthesia Drugs Market is hastily advancing, specifically in the use of Sevoflurane, Desflurane, Isoflurane, and other inhalation anesthesia drugs.

Non-dispersive Infrared (NDIR) Market worth $965 million by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, April 2, 2024
Carbon, Condensate, Gas, Temperature, Health, PLC, Transport, Isoflurane, HVAC, Sevoflurane, Lidar, Oxygen, Honeywell, OTDR, Capnography, SCADA, Row, Anesthesia, Controller, Security alarm, Desflurane, Air pollution, Region, Oil, Thermography, Environmental monitoring, Textile, COVID-19, MSA, Digital, VOC, Yokogawa Electric, Amphenol, Carbon dioxide, Brownfield land, Nitrous oxide, Natural gas, Carbon monoxide, Mining, Acoustic, Environment, Optical fiber, Volatile organic compound, Plastic, Atmosphere, Water, Power, Hardware

Based on application type, the NDIR market for monitoring applications is expected to hold the highest market share during the forecast period.

Key Points: 
  • Based on application type, the NDIR market for monitoring applications is expected to hold the highest market share during the forecast period.
  • Monitoring of refrigerant gases, capnography etc are likely to boost NDIR market.
  • NDIR market for VOCs to hold high market share during the forecast period.
  • Industrial & Manufacturing segment by vertical in NDIR industry to hold high market share during the forecast period.

Non-dispersive Infrared (NDIR) Market worth $965 million by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, April 2, 2024
Carbon, Condensate, Gas, Temperature, Health, PLC, Transport, Isoflurane, HVAC, Sevoflurane, Lidar, Oxygen, Honeywell, OTDR, Capnography, SCADA, Row, Anesthesia, Controller, Security alarm, Desflurane, Air pollution, Region, Oil, Thermography, Environmental monitoring, Textile, COVID-19, MSA, Digital, VOC, Yokogawa Electric, Amphenol, Carbon dioxide, Brownfield land, Nitrous oxide, Natural gas, Carbon monoxide, Mining, Acoustic, Environment, Optical fiber, Volatile organic compound, Plastic, Atmosphere, Water, Power, Hardware

Based on application type, the NDIR market for monitoring applications is expected to hold the highest market share during the forecast period.

Key Points: 
  • Based on application type, the NDIR market for monitoring applications is expected to hold the highest market share during the forecast period.
  • Monitoring of refrigerant gases, capnography etc are likely to boost NDIR market.
  • NDIR market for VOCs to hold high market share during the forecast period.
  • Industrial & Manufacturing segment by vertical in NDIR industry to hold high market share during the forecast period.

Global Inhalation Anesthesia Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts

Retrieved on: 
Friday, January 20, 2023
Piramal Group, Sevoflurane, Hypoventilation, Desflurane, Merck Group, COVID-19, Inhalation, Baxter International, Anesthesia, Isoflurane, Prevalence, R, Hospital, Patient, Operating, AbbVie, Nitrous oxide, Asthma, Anesthetic, Research, Semiconductor, Dentistry, Pharmaceutical industry, Potash, Growth

DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Inhalation Anesthesia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Inhalation Anesthesia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global inhalation anesthesia market size reached US$ 1.5 Billion in 2021.
  • Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery.
  • What is the structure of the global inhalation anesthesia market and who are the key players?

Insights on the Inhalation Anesthesia Global Market to 2027 - Increasing Prevalence of Chronic Medical Disorders Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 17, 2023
Health, Pharmaceutical, Hospital, Anesthetic, Inhalation, R, COVID-19, Desflurane, Nitrous oxide, Sevoflurane, Growth, Anesthesia, Patient, Prevalence, Paola Lattus, Research, Asthma, Isoflurane, Hypoventilation, Pharmaceutical industry, Dentistry

Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery.

Key Points: 
  • Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery.
  • Some of the commonly used inhalation anesthetics include nitrous oxide, desflurane, isoflurane and sevoflurane.
  • The increasing prevalence of chronic medical disorders requiring surgical treatments is one of the key factors driving the growth of the market.
  • The publisher provides an analysis of the key trends in each sub-segment of the global inhalation anesthesia market report, along with forecasts at the global, regional and country level from 2022-2027.

Sedana Medical receives FDA Fast Track Designation in the United States

Retrieved on: 
Wednesday, January 4, 2023
Richmond Agitation-Sedation Scale, Patient, Fast track (FDA), Communication, Respiratory failure, Food, Accelerated approval (FDA), Fast Track, Propofol, Inhalation sedation, Certification, III, FN, ICU, New Drug Application, FDA, Safety, Priority review, News, FTD, White Light Rock & Roll Review, NDA, Isoflurane, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RASS, Pharmaceutical industry, Medical device, Weapon, Nordic

Fast Track is a process designed to facilitate the development, and expedite the review of therapies that treat serious conditions and fill an unmet medical need.

Key Points: 
  • Fast Track is a process designed to facilitate the development, and expedite the review of therapies that treat serious conditions and fill an unmet medical need.
  • Sedana Medical is aiming for a combination registration of the medical device Sedaconda ACD and the pharmaceutical isoflurane for sedation of mechanically ventilated intensive care patients in the United States.
  • Sedana Medical will engage in discussions with the FDA on how the development program can benefit from the FTD.
  • Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.

Sedana Medical receives FDA Fast Track Designation in the United States

Retrieved on: 
Wednesday, January 4, 2023
Richmond Agitation-Sedation Scale, Patient, Fast track (FDA), Communication, Respiratory failure, Food, Accelerated approval (FDA), Fast Track, Propofol, Inhalation sedation, Certification, III, FN, ICU, New Drug Application, FDA, Safety, Priority review, News, FTD, White Light Rock & Roll Review, NDA, Isoflurane, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RASS, Pharmaceutical industry, Medical device, Weapon, Nordic

Fast Track is a process designed to facilitate the development, and expedite the review of therapies that treat serious conditions and fill an unmet medical need.

Key Points: 
  • Fast Track is a process designed to facilitate the development, and expedite the review of therapies that treat serious conditions and fill an unmet medical need.
  • Sedana Medical is aiming for a combination registration of the medical device Sedaconda ACD and the pharmaceutical isoflurane for sedation of mechanically ventilated intensive care patients in the United States.
  • Sedana Medical will engage in discussions with the FDA on how the development program can benefit from the FTD.
  • Sedana Medical was founded in 2005, is listed on Nasdaq First North Growth Market (SEDANA) and headquartered in Stockholm, Sweden.

Inhalation Anesthesia Global Market Report 2022: Increased Safety for Geriatric Patients Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 27, 2022
General Health, Seniors, Consumer, Health, Pharmaceutical, Sevoflurane, Muscle, Dermatology, Growth, Vecuronium bromide, Anesthesia, Blood, Acquisition, Isoflurane, Patient, Dental care, Compliance, Population, Injection, Nitrous oxide, Ageing, Dechra Pharmaceuticals, Hospital, Maintenance, United Nations, Pain management, Degenerative disease, Therapy, Endocrinology, Ophthalmology, Desflurane, Asia-Pacific, Dentistry, Pharmaceutical industry

The "Inhalation Anesthesia Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhalation Anesthesia Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • North America was the largest region in the inhalation anesthesia market in 2021.
  • The regions covered in the inhalation anesthesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • Therefore, the increasing geriatric population is expected to boost demand for inhalation anesthesia during the forecast period.

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Retrieved on: 
Tuesday, October 11, 2022
ISO, Cannabidiol, TBI, COPD, Rheumatoid arthritis, ASX, Bronchitis, IND, New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, U.S. FDA, Drug development, OSA, Spatial memory, Asthma, Investigational New Drug, Traumatic brain injury, NFL, Isoflurane, Addiction, Drug discovery, Private Securities Litigation Reform Act, Australian Securities Exchange, Food, Company, Marketing, American depositary receipt, Pain, Patent, Chief scientific officer, Anxiety, Sleep apnea, GLOBE, Inflammatory bowel disease, Concussion, FDA, Solution, Pharmaceutical industry, Medical device, CBD, Nasdaq

IHL-216A is Incannexs proprietary combination of cannabidiol (CBD) and isoflurane (ISO) that is being developed for treatment of TBI.

Key Points: 
  • IHL-216A is Incannexs proprietary combination of cannabidiol (CBD) and isoflurane (ISO) that is being developed for treatment of TBI.
  • Incannex submitted a pre-IND meeting package to the FDA in August 2022.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said: Feedback from the FDA in the pre-IND meeting indicated that the agency is highly interested in the development of IHL-216A for treatment of traumatic brain injury.
  • IHL-216A has demonstrated neuroprotective activity in two separate animal models of traumatic brain injury, one representing moderate to severe injury and the other representing mild injury, or concussion.

Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Retrieved on: 
Tuesday, August 2, 2022
Composition, AMRI, CBD, Brain, Memorial Day, Hematoma, Anxiety, Good manufacturing practice, U.S. FDA, Traumatic brain injury, CGMP, Food, R, Rheumatoid arthritis, Nerve, Brain damage, Concussion, Isoflurane, Amnesia, American depositary receipt, Sleep apnea, Inflammatory bowel disease, Compliance, Incidence, Australian Securities Exchange, Private Securities Litigation Reform Act, Neuroinflammation, Patent, GMP, Genta (company), Safety, ASX, Asthma, NASDAQ, Injury, Achievement, CA2, Clinical trial, US Foods, FDA, Method, Food and Drug Administration, Patient, Sport, TBI, COPD, OSA, Russell T Davies, Bronchitis, CA1, IND, Pharmaceutical industry, Medical device, Medical imaging, Fine chemical, Allograft inflammatory factor 1

MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').

Key Points: 
  • Curia is engaged to scale-up the fill-finish manufacture of IHL-216A in compliance with Current Good Manufacturing Practice ('cGMP').
  • Incannex Chief Scientific Officer Dr Mark Bleackley said; "Scaling up cGMP manufacture of IHL-216A is an exciting step in the development of our product and represents a critical milestone for delivering an inhaled drug, such as IHL-216A.
  • "Curia is honoured to be partnering with Incannex as it addresses an area of unmet patient need," said Chris Conway, president, R&D, Curia.
  • Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise.